LLY250103C665000
- 0.00
- 0.000.00%
Eli Lilly and Co Newsroom
Eli Lilly's (NYSE:LLY) Dividend Will Be Increased To $1.50
Novo Nordisk Seeks to Block Compounded Victoza
Santa Clause Came and Went Without Bringing Gifts | Weekly Buzz
Friday? More Like Grinch Day | Wall Street Today
Smart Money Is Betting Big In LLY Options
Viking Therapeutics Among Potential Buyout Candidates: Oppenheimer
Santa Claus Came Without Rallying the Troops | Live Stock
Jim Cramer Says Lazard Is 'Really Inexpensive,' Recommends Buying This Tech Stock
Eli Lilly and Company (LLY) Is Attracting Investor Attention: Here Is What You Should Know
Eli Lilly Joins FDA Lawsuit Over Compounded Obesity Drugs, Seeks 'Swift End' And 'To Protect Its Interests'
The 15.92% Average Gain in Inauguration Year: Will Trump's Second Term Echo the Trend?
Don't Buy Weight-Loss Medication From Unauthorized Sources, UK Health Agency Warns About Risks
Weight Loss Drugs Can Cut Grocery Spending by up to 9%: Study
Insurance is not covered, supply shortages, rampant generic drugs, slow new drug development, and new weight-loss medications still face challenges.
New GLP-1 weight loss drugs are not only changing the lives of obese populations but also creating billions of dollars in revenue for pharmaceutical companies like Eli Lilly and Co and Novo-Nordisk A/S. However, analysis indicates that weight loss drugs currently face some challenges in the USA: there is the risk of insurance companies refusing to pay, and ongoing supply shortages have created opportunities for lower-priced generic drugs. Additionally, it remains uncertain whether pharmaceutical companies can truly develop better weight loss medications and what the new U.S. government's attitude toward weight loss drugs will be.
Jefferies Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $994
Eli Lilly Stock Upgraded to "Buy" as Analysts Boost Price Target to $1,250
US Employer Health Costs To Rise In 2025 Fueled By Weight Loss: Report
The three major US stock index futures rose collectively, and all seven giants were up in pre-market trading | Highlights for tonight.
① NVIDIA GB300 may be released in the second quarter of 2025; ② Eli Lilly and Co's weight loss drug tirzepatide has officially launched in China; ③ Apple announces price reductions.
Eli Lilly and Co (LLY.US) officially announced the launch of Mufangda (Tirzepatide) in China.
On January 2, 2025, Eli Lilly and Co announced the official launch of Mufengda (Teriparatide Injection) in China, covering two indications.
$100 Invested In Eli Lilly 15 Years Ago Would Be Worth This Much Today